Higher ferritin levels, but not serum iron or transferrin saturation, are associated with Type 2 diabetes mellitus in adult men and women free of genetic haemochromatosis
MetadataShow full item record
Context - Iron overload predisposes to diabetes and higher ferritin levels have been associated with diabetes. However, it is unclear whether ferritin reflects differences in iron-related parameters between diabetic and nondiabetic persons. We examined associations of serum ferritin, iron and transferrin saturation with Type 2 diabetes in adults without genetic predisposition to iron overload. Design, participants and measurements - Cross-sectional analysis of community-dwelling men and women aged 17–97 years from the Busselton Health Survey, Western Australia. Men and women carrying genotypes associated with haemochromatosis (C282Y/C282Y or C282Y/H63D) were excluded. Serum ferritin, iron and transferrin saturation were assayed. Results - There were 1834 men (122 with diabetes, 6·6%) and 2351 women (141 with diabetes, 6%). In men, higher serum ferritin was associated with diabetes after adjusting for age, smoking, alcohol, cardiovascular history, body mass index (BMI), waist, blood pressure, lipids, C-reactive protein (CRP), adiponectin, alanine transaminase (ALT) and gamma-glutamyl transpeptidase (GGT) [odds ratio (OR): 1·29 per 1 unit increase log ferritin, 95% confidence interval (CI) = 1·01–1·65, P = 0·043]. In women, higher serum ferritin was associated with diabetes [fully adjusted OR: 1·31 per 1 unit increase log ferritin, 95% CI = 1·04–1·63, P = 0·020; 1·84 for tertile (T) 3 vs T1, 95% CI = 1·09–3·11]. Neither iron levels nor transferrin saturation were associated with diabetes risk in men or women. Higher ferritin was not associated with insulin resistance in nondiabetic adults. Conclusions - In adults, higher ferritin levels are independently associated with prevalent diabetes while iron and transferrin saturation are not. Ferritin is a robust biomarker for diabetes risk, but further investigation is needed to clarify whether this relationship is mediated via iron metabolism.
Funding and Sponsorship
This is the peer reviewed version of the following article: Yeap, B. and Divitini, M. and Gunton, J. and Olynyk, J. and Beilby, J. and McQuillan, B. and Hung, J. et al. 2015. Clinical Endocrinology. 82 (4): pp. 525-532, which has been published in final form at http://doi.org/10.1111/cen.12529. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving at http://olabout.wiley.com/WileyCDA/Section/id-820227.html#terms
Showing items related by title, author, creator and subject.
Higher concentrations of serum iron and transferrin saturation but not serum ferritin are associated with cancer outcomesChua, A.; Knuiman, M.; Trinder, D.; Divitini, M.; Olynyk, John (2016)© 2016 American Society for Nutrition.Background: Although the carcinogenic potential of iron has been shown, evidence from observational studies that have linked serum iron variables and cancer outcomes has been inconsistent. ...
McKinnon, E.; Rossi, E.; Beilby, J.; Trinder, D.; Olynyk, John (2014)Background & Aims: Serum levels of ferritin are commonly measured to assess iron stores but are affected by factors such as obesity and chronic disease. Published reference ranges have not changed in decades, and the ...
Characterization of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysisHolman, R.; Olynyk, John; Kulkarni, H.; Ferrari, P. (2017)Background: Parenteral iron is integral in the treatment of anaemia of chronic kidney disease patients on haemodialysis (HD). However, increased liver iron concentration (LIC) can result from such treatment, and this ...